抗結核薬による肝損傷に対する代謝機能障害に関連するステアトス性肝疾患の影響
1Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China.
Medicine
|September 3, 2025
まとめ
抗結核薬による肝損傷 (AT- DILI) は,代謝機能障害に関連するステアトス性肝疾患 (MASLD) の患者の23. 3%で発生しました. 低体量指数 (BMI) と高いFibrosis- 4 (FIB- 4) のスコアは,この集団におけるAT- DILIの重要な危険因子である.
科学分野:
- ヘパトロジー
- 薬理学について
- 感染症
背景:
- メタボリック機能障害に関連した脂肪性肝疾患 (MASLD) が増加しています.
- 抗結核薬は不可欠ですが,肝臓に損傷を与える可能性があります.
- 結核治療を受けているMASLD患者の薬物誘発性肝損傷の特定のリスクは十分に理解されていません.
研究 の 目的:
- MASLD患者における抗結核薬による肝損傷 (AT- DILI) の発生率を決定する.
- この患者群でAT- DILIに関連した危険因子を特定する.
主な方法:
- 2017年12月から2023年3月までの間に結核治療を受けた120人のMASLD患者の遡及的レビュー.
- 患者はAT- DILI群と非AT- DILI群に分けられました.
- リスク要因を特定するために,物流回帰分析を使用した.
主要な成果:
- AT- DILIの発生率は23. 3% (28人/120人) であった.
- 肝損傷は軽度から急性肝不全まであり,肝細胞損傷が最も一般的であった.
- 重要なリスク要因は,低体量指数 (BMI) と高Fibrosis- 4 (FIB- 4) でした.
結論:
- 結核治療を受けたMASLD患者では,AT- DILIの発生率がかなり高い.
- 低いBMIと高いFIB-4スコアは,AT-DILIリスクの増加の主要な指標です.
- 臨床医は,結核の治療中にこれらの危険因子を有するMASLD患者を注意深く監視すべきである.
関連する概念動画
Pulmonary Tuberculosis I
321
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
321
Hepatic Drug Excretion: Influencing Factors
214
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
214
Pulmonary Tuberculosis V
237
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
237
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
370
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
The drug's acidity or basicity is essential in...
370
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
79
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
79
Hepatic Drug Excretion: Enterohepatic Cycling
1.7K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.7K


